Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
- Conditions
- Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2220
- Registration Number
- NCT01516541
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT01516476
A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01514968
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01513083
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 355
- Registration Number
- NCT01512420
A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT01510899
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 672
- Registration Number
- NCT01508130
- Locations
- 🇺🇸
Florida Center for Gastroenterology, Largo, Florida, United States
🇺🇸HMRI Liver Center, Pasadena, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT01507168
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇫🇷Hôpital Saint Antoine; Service Hépathologie, Paris, France
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Capecitabine/OxaliplatinDrug: Fluorouracil/Folinic Acid/OxaliplatinDrug: Fluorouracil/Folinic Acid/Irinotecan
- First Posted Date
- 2012-01-09
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 719
- Registration Number
- NCT01506167
- Locations
- 🇬🇧
Walsall Manor Hospital, Walsall, United Kingdom
🇬🇧University Hospital of North Staffordhire, Blackpool, United Kingdom
🇬🇧Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre, Bath, United Kingdom
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 217
- Registration Number
- NCT01494688
- Locations
- 🇫🇷
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
🇺🇸Univ of Pennsylvania Med Ctr, Philadelphia, Pennsylvania, United States
🇫🇷Institut Curie; Oncologie Medicale, Paris, France